Evaluation of acquired and hereditary risk factors for the development of thromboembolism in patients with systemic lupus erythematosus.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
10
11
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
Although the contribution of antiphospholipid antibodies (aPL) to thrombolembolism in systemic lupus erythematosus (SLE) is well known, there is not enough data on the contribution of various hereditary thrombophilic factors. In this study, we aimed to determine acquired and hereditary thrombophilic factors in adult patients with SLE. A total of 93 SLE patients (87 women and 6 men) were included. Data on clinical, demographic and laboratory characteristics, and disease activity scores (SLEDAI) of the patients were evaluated. The patients were analyzed with a screen, including lupus anticoagulant, anticardiolipin antibodies (aCL), antithrombin III, protein C, protein S, and homocysteine levels; factor V Leiden ( FVL ), methylenetetrahydrofolate reductase ( MTHFR ) and prothrombin G20210A gene mutations. A total of 23 thromboembolic events were reported in 17 (18.3%) of the patients. The frequency of pregnancy complications and SLEDAI scores were significantly higher in SLE patients who had a thromboembolism event ( P < 0.05). Thromboembolism was detected in 12 (32.4%) of 37 patients with positive aPL antibody and 5 (8.9%) of 56 patients with negative aPL antibody ( P = 0.006). In addition, thromboembolism developed in 11 (32.3%) of 34 lupus anticoagulant-positive patients and 6 (10.1%) of 59 lupus anticoagulant-negative patients ( P = 0.012). Moreover, protein C levels were significantly lower in patients who developed thromboembolism ( P < 0.05). Patients with and without thromboembolism were similar in terms of genetic thrombophilia factors ( MTHFR A1298C, MTHFR C677T, FVL and Prothrombin G20210A ) ( P > 0.05). In conclusion, in the current study, some acquired (aPL, lupus anticoagulant and cCL IGG) and hereditary (protein C deficiency) thrombophilic factors were shown to be associated with the development of thrombosis in SLE patients. However, the effect of other hereditary factors on the development of thromboembolism could not be demonstrated. According to the data of this study, genetic screening seems inappropriate in terms of the risk of thromboembolism in patients with SLE.
Identifiants
pubmed: 37756208
doi: 10.1097/MBC.0000000000001253
pii: 00001721-990000000-00104
doi:
Substances chimiques
Lupus Coagulation Inhibitor
0
Protein C
0
Prothrombin
9001-26-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
478-486Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun 2019; 96:1–13.
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82:299–308.
Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol 2018; 14:1043–1053.
Wu XY, Yang M, Xie YS, Xiao WG, Lin J, Zhou B, et al. Causes of death in hospitalized patients with systemic lupus erythematosus: a 10-year multicenter nationwide Chinese cohort. Clin Rheumatol 2019; 38:107–115.
Hinojosa-Azaola A, Romero-Diaz J, Vargas-Ruiz AG, Nuñez-Alvarez CA, Cicero-Casarrubias A, Ocampo-Torres MC, Sanchez-Guerrero J. Venous and arterial thrombotic events in systemic lupus erythematosus. J Rheumatol 2016; 43:576–586.
Sarabi ZS, Chang E, Bobba R, Ibanez D, Gladman D, Urowitz M, Fortin PR. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum 2005; 53:609–612.
de Groot PG, de Laat B. Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. Best Pract Res Clin Rheumatol 2017; 31:334–341.
Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol 2016; 3:75–84.
Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52:2774–2782.
Chang ER, Pineau CA, Bernatsky S, Neville C, Clarke AE, Fortin PR. Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus. J Rheumatol 2006; 33:1780–1784.
Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multiethnic cohort. Ann Rheum Dis 2009; 68:238–241.
White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: (23 Suppl 1): I4–I8.
Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004; 114 (5–6):593–595.
Yuan W, Guan F. Thrombosis and anticoagulation therapy in systemic lupus erythematosus. Autoimmune Dis 2022; 2022:3208037.
Aday AW, Duran EK, Van Denburgh M, Kim E, Christen WG, Manson JE, et al. Homocysteine is associated with future venous thromboembolism in 2 prospective cohorts of women. Arterioscler Thromb Vasc Biol 2021; 41:2215–2224.
Sam NB, Zhang Q, Li BZ, Li XM, Wang DG, Pan HF, Ye DQ. Serum/plasma homocysteine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Clin Rheumatol 2020; 39:1725–1736.
Giannelou M, Nezos A, Fragkioudaki S, Kasara D, Maselou K, Drakoulis N, et al. Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis. Clin Immunol 2018; 193:110–117.
Stojan G, Li J, Liu T, Kane MA, Petri MA. Intracellular homocysteine metabolites in SLE: plasma S-adenosylhomocysteine correlates with coronary plaque burden. Lupus Sci Med 8 (2021):e000453.
Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004; 104:143–148.
Sallai KK, Nagy E, Bodó I, Mohl A, Gergely P. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol 2007; 36:198–205.
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677–2686.
Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29:288–291.
Petri M, Nelson L, Weimer F, Anderson D, Darlington T, Corash L. The automated modified Russell viper venom time test for the lupus anticoagulant. J Rheumatol 1991; 18:1823–1825.
Klein A, Molad Y. Hematological manifestations among patients with rheumatic diseases. Acta Haematol 2021; 144:403–412.
Ibrahim AAG, Shadi HWE, Elamin AAY, Draz HE. Retrospective cohort study of thromboembolic events in systemic lupus erythematosus with or without secondary antiphospholipid syndrome and their correlation to lupus activity and dyslipidemia. Egypt Rheumatol Rehabil 2023; 50:10.
Park DJ, Yoon CS, Choi SE, Xu H, Kang JH, Lee SS. Risk factors for thrombotic events in Korean patients with systemic lupus erythematosus. Sci Rep 2021; 11:23529.
Reynaud Q, Lega JC, Mismetti P, Chapelle C, Wahl D, Cathébras P, Laporte S. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2014; 13:595–608.
Demir S, Li J, Magder LS, Petri M. Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. Rheumatology (Oxford) 2021; 60:3770–3777.
Pengo V, Testa S, Martinelli I, Ghirarduzzi A, Legnani C, Gresele P, et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res 2015; 135:46–49.
Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; 36:1195–1199.
Domingues V, Magder LS, Petri M. Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. Lupus Sci Med 2016; 3:e000107.
Khawaja M, Magder L, Goldman D, Petri MA. Loss of antiphospholipid antibody positivity postthrombosis in SLE. Lupus Sci Med 2020; 7:e000423.
Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 2016; 41:154–164.
Deloughery TG, Hunt BJ, Barnes GD, Connors JM. WTD Steering Committee. A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing. Res Pract Thromb Haemost 2022; 6:e12739.
Robeva R, Tanev D, Andonova S, Nikolova M, Tomova A, Kumanov P, et al. Inherited thrombophilias could influence the reproductive outcome in women with systemic lupus erythematosus. Balkan J Med Genet 2017; 20:21–26.
Xiang T, Xiang H, Yan M, Yu S, Horwedel MJ, Li Y, Zeng Q. Systemic risk factors correlated with hyperhomocysteinemia for specific MTHFR C677T genotypes and sex in the Chinese population. Ann Transl Med 2020; 8:1455.
Topaloglu R, Akierli C, Bakkaloglu A, Aydintug O, Ozen S, Besbas N, Ozcelik T. Survey of factor V leiden and prothrombin gene mutations in systemic lupus erythematosus. Clin Rheumatol 2001; 20:259–261.
Wypasek E, Undas A. Protein C and protein S deficiency - practical diagnostic issues. Adv Clin Exp Med 2013; 22:459–467.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295–306.
Wei L, Xie H, Yan P. Prognostic value of the systemic inflammation response index in human malignancy: a meta-analysis. Medicine (Baltimore) 2020; 99:e23486.
Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, Liu L. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep 2019; 9:3284.